Chonnam Med J.
2002 Mar;38(1):73-77.
A Clinical Study of Moxifloxacin for the Lower Respiratory Infections
- Affiliations
-
- 1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. kyc0923@chonnam.ac.kr
- 2Department Anesthesiology, Chonnam National University Medical School, Gwangju, Korea.
- 3Department Clinical Pathology, Chonnam National University Medical School, Gwangju, Korea.
- 4Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.
Abstract
- Moxifloxacin is a newly developed drug which is more potent and safe than previous fluoroquinolones. This drug is known to be effective in treating lower respiratory tract infections by gram-positive and gram-negative organisms. Moreover, moxifloxacin is effective to beta-lactamase-producing or other resistant bacteria. We observed the clinical efficacy and safety of oral moxifloxacin taken 400mg once a day for 7 days in patients with lower respiratory tract infection. Clinical effects were evaluable in 16 patients. Their pre-test diagnosis were bronchiectasis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, and other lower respiratory infections. Clinical success was noted in 15 (93.8%) of 16 moxifloxacin-treated patients, and 7 (43.8%) patients were judged to be cured clinically. Among the respiratory symptoms and signs, sputum (p=0.001) and cough (p=0.002) were more easily improved than fever and dyspnea. Adverse reactions were reported by 3 patients. Their complaints were nausea, fatigue, and thirsty. No other significant laboratory abnormalities related to moxifloxacin were observed. This study demonstrated that a 7-day course of moxifloxacin 400 mg once daily was effective and safe for the treatment of adult lower respiratory tract infections.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Activity of Moxifloxacin Against Ofloxacin-Resistant Mycobacterium Tuberculosis: A Study of Cross-Resistance Between Ofloxacin and Moxifloxacin
- Clinical evaluation of cefodizime in lower respiratory tract infections
- A Multicenter, Randomized, Open, Comparative Study for the Efficacy and Safety of Oral Moxifloxacin 400 mg Once a Day and Clarithromycin 500 mg Twice Daily in Korean Patients with Acute Exacerbations of Chronic Bronchitis
- Moxifloxacin Ameliorates Oleic Acid-induced Acute Lung Injury by Modulation of Neutrophilic Oxidative Stress in Rats
- The Epidemiology of Viral Lower Respiratory Tract Infections
